Redefining In-Breast Tumor Recurrence: Unveiling Metastatic Dynamics and Shifting the Focus to Overall Survival in Breast Cancer Surgery Assessment Authors: Kefah Mokbel, Munaser Alamoodi Published: 2023 INTRODUCTION We were intrigued by Cheun et al.’s [1] recently published article, revealing a 61% increased risk of in-breast tumor recurrence (IBTR) in 5,598 patients undergoing breast conservation with positive resection margins at the initial lumpectomy, despite achieving negative resection through repeated excisions. This increased risk was prominent in young patients and those with treatment delays. The authors effectively controlled for confounding variables, confirming that the impact of technical failures on IBTR was adequately mitigated. Initially, the authors considered the increased risk of IBTR with positive resection margins to stem from the biologically aggressive nature of the disease, residual disease left due to technical failure, or a combination of both. The presented data ruled out technical failure as a significant factor, given that repeated excisions eliminated the risk of residual disease near the primary tumor. We agree with the authors who attributed the observed risk to tumor biology, suggesting that additional surgery to achieve negative margins might offer minimal benefits. While the authors explored the association between resection margins/repeat excisions and IBTR, as well as IBTR-free survival, the article lacks data on distant metastatic disease and overall survival (OS). However, the potential biological mechanisms underlying these findings remain unclear. In this context, we present a biological rationale for these findings. THE HYPOTHESIS Mounting evidence supports the efficacy of breast-conserving therapy (BCT) in enhancing OS and breast cancer-specific survival (BCSS) across diverse subtypes compared to mastectomy [2]. However, extended follow-up studies have uncovered a heightened risk of locoregional recurrence (LRR) with BCT compared with mastectomy [3]. Early breast cancer exhibits systemic characteristics as evidenced by the presence of circulating tumor cells (CTCs) in the peripheral circulation [4]. Positive resection margins are likely to result in the release of more CTCs. Significant scientific data underscore the critical role of the tumor microenvironment (TME) in fostering the survival and dissemination of breast cancer cells. Tumor cells actively shape the surrounding breast microenvironment by imprinting their unique molecular signatures [5]. Although CTCs and dormant disseminated tumor cells (DTCs) may not immediately induce clinical metastasis, they can remain dormant in low numbers within the peripheral circulation and bone marrow for decades. The metastatic niche, characterized by a complex environment of cytokines, chemokines, hormones, and soluble factors, plays a crucial role in guiding these cells towards either dormancy or proliferation, ultimately leading to detectable metastases. Intrinsic genetic mutations and extrinsic weakening of the host immune system can reactivate these cells, with epithelial-mesenchymal transition playing a key role [5]. We propose that reactivated CTCs and DTCs possess innate breast-homing capabilities and tend to return to the breast of origin, where the molecular infrastructure of the TME fosters tumor cell proliferation and survival, leading to IBTR or regional recurrence. Notably, chemokine receptors CXC motif chemokine receptor 4 (CXCR4) and C-C chemokine receptor type 7 are upregulated in human breast cancer cells and stromal elements, with their ligands displaying peak expression levels in organs that serve as primary sites for breast cancer metastasis [6]. The stromal cell-derived factor 1 (SDF-1)-rich TME of the breast of origin is posited to attract reactivated CXCR4+ CTCs, facilitating adhesion, extravasation, and subsequent tumor growth [6]. Breast homing is a more viable option for reactivated CTCs than preparing a pre-metastatic niche in other organs [5]. Our hypothesis suggests that BCT is correlated with a lower incidence of fatal distant metastasis and superior OS compared to mastectomy. Conversely, a higher incidence of IBTR after BCT is anticipated, which is consistent with clinical observations [2,3]. The observation that 95% of IBTRs occur in or near the same quadrant as the index cancers, even after achieving tumor-free margins following BCT, further supports our hypothesis. This is because the index quadrant is likely to contain potent TME elements, such as SDF-1 [5,6], facilitating the growth of reactivated CXCR4+ CTCs and DTCs that infiltrate the site. However, the TME extends beyond the index quadrant to encompass the entire breast and axilla [5]. Our proposed hypothesis aligns with the emerging recognition that IBTR could signal a metastatic event in many cases rather than the progression of residual local disease, as evidenced by the substantial risk of mortality after an isolated local recurrence compared with a second primary tumor [7]. Witteveen et al. reported a 10-year OS rate of 84% in women without recurrence, 49% in women with LRR, and 72% in women with a second primary tumor in the ipsilateral breast. Additionally, Bidard et al. [8] noted a significant correlation between CTC counts before neoadjuvant chemotherapy and locoregional relapse (hazard ratio, 3.02; 95% confidence interval [CI], 1.88–4.75), further supporting our hypothesis. Considering this evolving paradigm shift in the understanding of breast cancer, patients and specialists should prioritize BCT for treating the primary tumor whenever feasible, given that mastectomy could lead to an inferior OS. Furthermore, the OS benefit of BCT over mastectomy appeared to extend to ipsilateral breast cancer recurrence in patients previously treated with breast-conserving surgery (BCS) or radiotherapy (RT). This finding is supported by a recent meta-analysis, where repeat BCS (with or without repeat RT) correlated with improved OS (risk ratio, 1.040; 95% CI, 1.003–1.079; p = 0.032; I2 = 70.8%) [9]. Gentile et al. [10] recently reported that patients undergoing BCS for triple-negative or human epidermal growth factor receptor 2-enriched IBTR demonstrated significantly improved distant-disease-free survival, OS, and BCSS compared to those undergoing mastectomy (p = 0.009, p = 0.002, and p = 0.001, respectively). This evolving understanding promises to enhance our ability to develop more effective therapeutic strategies and is likely to lead to further de-escalation of breast cancer surgery. CONCLUDING REMARKS IBTR is not always indicative of the local progression of residual disease or a second primary disease. Instead, it may signify a metastatic event fueled by reactivated CTCs with innate breast homing capabilities, influenced by chemokines, and primarily linked to tumor biology. Positive resection margins may release additional CTCs, explaining the elevated incidence of IBTR, despite achieving clear margins through repeat excision post-lumpectomy. Therefore, the assessment of the effectiveness of breast cancer surgery should focus on OS rather than IBTR. Aggressive surgery for the primary tumor or IBTR is unlikely to significantly enhance OS. Footnotes Conflict of Interest: The authors declare that they have no competing interests. Author Contributions: Conceptualization: Mokbel K.Supervision: Mokbel K.Writing - original draft: Mokbel K.Writing - review & editing: Mokbel K, Alamoodi M. Conceptualization: Mokbel K. Conceptualization: Mokbel K. Supervision: Mokbel K. Supervision: Mokbel K. Writing - original draft: Mokbel K. Writing - original draft: Mokbel K. Writing - review & editing: Mokbel K, Alamoodi M. Writing - review & editing: Mokbel K, Alamoodi M. References